It would be nice if GALT is FIRST to come up with a cure of Liver Diseases; but it's also going to be almost as good if GALT is 2nd, or 3rd.
IF GALT follows the same pattern of CNAT & GALT has favorable P2 results that are released at the end of 3rd quarter, then that merely means 9 million or more share are traded on the announcement, same thing if GALT announces FAST TRACK by the FDA, but still the stock languishes at a stock price of less than $2.00
IF GALT has favorable test results at the end of Q3 & they begin P3 testing then the only things that is going to cause GALT stock price to move over $2.00 would be the announcement of a partnership with BIG PHARMA, either than or sit tight & wait 3 years for the P3 Tests results & FDA approval.
Does anyone really think GALT stock price will move over $2.00 EVEN IF favorable P2 test results are announced at end of Q3? CNAT stockholders have been bitterly disappointed their stock price hasn't moved up on the FAST TRACK announcement, I know, because I'm a shareholder of both companies.
All of the above is just my opinion; I'm not expecting GALT stock price to jump if if Q3 Test data is wildly favorable.
The day AFTER the Super Bowl, GALT is scheduled to present to investors @1000, 8 Feb. I'm hoping someone will attend. I'd like to know the size of the audience & their reaction to the presentation as well as anything new that is said during the presentation.
CNAT will be presenting on TUESDAY, @1500.
YES, I'm a shareholder in both companies.
CNAT CEO will offer a presentation @1500; Tuesday, 9 Feb. I'm hoping someone will be attending & give us a report on the size of the audience & gauge their reaction.
The presentation is @0800; 8 Feb 2016, @BIO-CEO Conference. This will be the day AFTER the Super Bowl.
Will you/ANYONE (¿) be attending? I'd be interested to know how the audience (if there is an audience) reacted/responds.
You might consider attending the BioCEO conference in NY on 8-9 Feb; CNAT, GALT, & many other CEO's will be attending. Listen to presentations & talk to the CEO's first hand.
The article is entitled, :"Fatty Liver Disease, Motivation to Lose Weight". Simply go to GALT's website.
A MUST read for shareholders & PROSPECTIVE shareholders.
Thanks for taking the time to explain to me, what FAST Track is all about. It's definitely a good thing for any company to get when trying to get FDA approval for a new drug.
SOoooo WHAT? What is your point? Everyone knows the trial completion date. Your redundancy is stating the obvious.
GALT is definitely a t-h-i-nnnn-l-y traded stock. In my opinion, investors are simply sitting on the sidelines waiting for P2 test results to be released. Right now, to me, it appears $1.50 is a resistance level, meaning there is more downside risk than upside potential. Will $1.25 continue to be a support level, that is the big question mark in my mind?
Good topic bionicsunday
HAMMERED¿ What the heck are you talkin' 'bout. GALT has been traded within a range of $1.48 - $1.24 since January 8th, which is nearly a month. If GALT had declined in price 15% or more in the same time frame, then I suppose a person could legitimately use the "hammered" adjective. C'mon, bionicsunday, get REAL. Your silly notion of GALT being "hammered" has no more substance to it than the tooth fairy.
Jim Czirr is still on the board of Directors, it's just he is no longer Chairman of the Board. Jim is still an active member of the BOD's. My understanding is he is still in good "standing" with the other members of the board.
An Overview of Non-Invasive Testing in Liver Fibrosis.
IF you are a shareholder or prospective shareholder this article is a MUST READ.
I've watched & listened to the presentation 3 times; each time I picked up on something I'd missed before. My TWO take-aways,,,,,(1) was a better understanding of the science & that GALT is focusing on the most severe cirrohiss cases of liver disease & (2) I liked Dr. Traber being straightforward is assessing how GALT is doing compared to the development of competitor products & putting it terms of time.
All shareholders & prospective shareholders should watch this presentation several times if you want a better understanding of GALT's scientific approach.
Please add your reply to this topic & let us know what your take-aways are AFTER watching the presentation.
This is the topic of Dr Traber's CEO Perspective, dated 20 Jan 2016. You can read this article by going to GALT's website.
Hopefully, sometime Friday, GALT will have made it possible for us to watch/listen to Dr Traber's presentation in Florida, which was earlier today.
With a video of the presentation, hepatologists all over the world that are unable to attend, can go online & view the presentation, at their convenience.
You as a stockholder, can refer your investor friends to the video presentation by including a link in your email; now your investor friends that you are trying to convince to buy some GALT shares can see & listen to Dr Traber explain in detail, the science, directly to your investor friends. This seems to me like a Win-Win situation.
Now all you need to do as a stockholder is send out links to the video AFTER it is added to the website.
Question is, will you take the time to email a link to the video to your friends, family, relatives, co-workers?
I'm hoping GALT will videotape each & every "presentation" from now on. Putting those presentations on their website gives just that much more exposure of GALT's progress to people unable to attend.
I have a GTC order in for more shares within that same price range.
Good, on you, for deciding to put jsm on your IGNORE list.